Dr. Holtzman started a drug discovery program at WU in 2009 that runs in concert with the biotech (NuPeak Therapeutics) that he founded in 2012. Together, the program aims at discovering and developing small-molecule-kinase inhibitors to correct epithelial stem cell and innate immune cell reprogramming in the settings of post-viral inflammation and in cancer. The WU site focuses on the drug discovery phase using cell and animal models combined with medicinal chemistry and molecular pharmacology to move from structure-based drug design to proof of concept. The biotech concentrates on the drug development phase to deliver safety toxicology data for IND approval and initial clinical trials in humans. Current proprietary lead compounds are designed for the progressive post-viral respiratory disease found in asthma, COPD, and COVID-19 and for correcting related pathways found in breast, liver, and brain cancers.
Company Details
- Founded
- -
- Address
- 4320 Forest Park Ave, St Louis,missouri,united States
- Industry
- Biotechnology
- Keywords
- Show more similar pages.
- HQ
- St Louis, Missouri
Nupeak Therapeutics Inc. Questions
Nupeak Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/nupeak-therapeutics-inc
Nupeak Therapeutics Inc.'s industry is
Biotechnology
Nupeak Therapeutics Inc.'s top competitors are
Breath Analyzers Pte. Ltd.,
Raesedo Inc,
Breath Diagnostics, Inc.,
Voc-Advanced Breath Diagnostics Gmbh,
Arete Medical Devices,
Modulation Therapeutics,
Blend Health (Armour Labs Ltd.),
Recens Respiratio,
Instatin Inc,
Aerodiagnostics, Llc.
Nupeak Therapeutics Inc.'s categories are Biotechnology
Nupeak Therapeutics Inc.'s founding year is 2012
